Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 11/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 10/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 9/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 9/20 | 0.54 |
| ▸ | ADRA1D | P25100 | 9/20 | 0.54 |
| ▸ | ADRA1B | P35368 | 9/20 | 0.54 |
| ▸ | HTR7 | P34969 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.48 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5612487 | 0.85 | ADRA2A (0.56) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL29412295 | 0.77 | ADRA2A (0.65) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL5611436 | 0.76 | ADRA2A (0.58) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL5612448 | 0.75 | ADRA2A (0.61) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL31442157 | 0.74 | ADRA2A (0.64) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Tolonidine SCHEMBL310600 | 0.74 | ADRA2A (0.55) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| Tolonidine SCHEMBL29391908 | 0.74 | ADRA2A (0.55) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL5611947 | 0.74 | ADRA2A (0.48) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL11762970 | 0.71 | ADRA2A (0.63) | ADRA2AADRA1AADRA2BADRA2CADRA1D | |
| SCHEMBL29349477 | 0.71 | ADRA2A (0.63) | ADRA2AADRA1AADRA2BADRA2CADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007509897-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | claimed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | claimed |
| EP-1682110-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | Boehringer Ingelheim International GmbH (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| WO-2005046664-A1 | PHARMACEUTICAL COMPOSITION CONSISTING OF A BETA-3 ADRENOCEPTOR AGONIST AND AN ALPHA AGONIST | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154041-A1 | Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist | ADRB3, ADRB2, ADRB1 | ADRA2A 7/4885ADRA1A 6/4885ADRA2B 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.